Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T18:23:32.522Z.
Calculation as of: 2026-10-06T18:23:32.522Z.
Quote observation: 2026-10-06T18:07:43.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 967c3c4e1026402272b5761d24a9cd8122a999a0fe4ad26a1d84866f163ab752
PE RATIO
N/A
Market Cap
$59.03M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Xilio Therapeutics, Inc. (XLO) | $60.89M | N/A | N/A | N/A | N/A |
| Kalaris Therapeutics Inc (KLRS)vs › | $60.68M | N/A | N/A | N/A | N/A |
| Fractyl Health, Inc. (GUTS)vs › | $61.67M | N/A | N/A | N/A | N/A |
| Oncolytics Biotech Inc. (ONCY)vs › | $60.02M | N/A | N/A | N/A | N/A |
| Adicet Bio, Inc. (ACET)vs › | $59.78M | N/A | 110.41 | 110.41 | 110.41 |
| Connect Biopharma Holdings Limited (CNTB)vs › | $59.03M | N/A | N/A | N/A | N/A |
| Pliant Therapeutics, Inc. (PLRX)vs › | $62.85M | N/A | 45.99 | 45.99 | 45.99 |
| RenovoRx, Inc. (RNXT)vs › | $63.07M | N/A | N/A | N/A | N/A |
| Alps Group Inc (ALPS)vs › | $63.25M | N/A | N/A | N/A | N/A |
| Heron Therapeutics, Inc. (HRTX)vs › | $63.41M | N/A | 2.96 | 2.96 | 2.96 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$9.26
Forward EPS (Est.)
$-2.59
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
